Pith. sign in

REVIEW 4 major objections 6 minor 75 references

A mathematical model of CAR-T cell therapy in combination with chemotherapy for malignant gliomas

T0 review · 4 major / 6 minor · reviewed 2026-08-10 · deepseek-v4-flash

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗ Review JSON

Pith's one-line read A five-variable model of malignant glioma predicts that alternating CAR-T injections with temozolomide cycles more than doubles median survival in virtual patients.

desk verdict Plausible in silico case for alternating TMZ/CAR-T, but the argument depends on excluding double-resistant cells; worth refereeing, with robustness checks. read the letter →

arxiv 2501.13774 v2 pith:VAHSDG7Y submitted 2025-01-23 math.DS

Dmitry Sinelshchikov , Juan Belmonte-Beitia , Matteo Italia This is my paper · ORCID
classification math.DS MSC 34A3737N2592B05
keywords malignantgliomaCAR-Tcelltherapytemozolomidecombinationdrugresistanceinsilicoclinicaltrialimpulsivedynamicalsystemmathematicaloncology
verification ladder T0 review T1 audit T2 compute T3 formal

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The reading

The paper builds a mathematical model of malignant glioma growth under combined temozolomide chemotherapy and CAR-T cell immunotherapy, treating drug administrations as instantaneous pulses. It proves that a single round of both therapies only sends the tumor toward its carrying capacity, while constant administration above explicit dose thresholds can stabilize a tumor-free state. The central message from virtual trials is that alternating CAR-T injections between TMZ cycles, specifically the 5T2C5T and 1C5T1C5T protocols, yields the longest median survival, nearly 650 days, compared with 268 days untreated and 558 days with TMZ alone. If correct, this would argue for testing alternating schedules in clinical trials rather than delivering all of one therapy first.

What carries the argument

The engine is a five-dimensional compartmental ODE system with variables $S$ (cells sensitive to both therapies), $R_C$ (CAR-T-resistant, TMZ-sensitive cells), $R_E$ (TMZ-resistant, CAR-T-sensitive cells), $C$ (CAR-T cells), and $E$ (normalized TMZ efficacy decaying at rate $\mu$). Treatment is inserted as impulsive jumps $E \to E+E_0$ and $C \to C+v$, turning the continuous system into a hybrid model. The mathematical analysis uses invariant surfaces, including the carrying-capacity plane $K-S-R_C-R_E=0$ when no treatment acts, and the eigenvalues of the tumor-free equilibrium to extract dose thresholds. The same model then feeds population-scale virtual trials in which parameters are sampled uniformly and survival is measured as time to $10^{12}$ tumor cells.

What would settle it

Grow tumor cells under alternating TMZ and CAR-T exposure in vitro or in an animal model and measure whether a double-resistant subpopulation emerges while both treatments are present. If such double-resistant clones appear and proliferate at rates comparable to sensitive cells, the model's predicted median survival near 650 days would not be reproduced when the same protocol is simulated with that compartment added.

Watch

Extended reading notes

Core claim

On the paper's own terms, the central discovery is that the sequence and interleaving of chemotherapy and immunotherapy matter more than total dose: alternating TMZ cycles with CAR-T injections lets each therapy control the tumor population the other cannot, and this alternating concept is proposed as the optimal combined-treatment strategy. In silico trials over 10,000 virtual patients give median survival of 652–653 days at $10^9$ CAR-T cells and 688–689 days at $2\cdot 10^9$ for the two best alternating protocols, against 558 days for ten TMZ cycles alone. The paper also derives explicit threshold inequalities, $\bar{E}_0(\alpha_1+\epsilon_1)>r_1\mu$ and $\bar{v}> r_2(\bar{E}_0\alpha_3+\mu\rho_1)/(\mu\alpha_2)$, under which constant treatment makes the tumor-free equilibrium stable, and it shows that if TMZ-resistant cells grow twice as fast as sensitive cells, TMZ becomes counterproductive and CAR-T monotherapy becomes the best option.

Load-bearing premise

The model assumes there are no tumor cells resistant to both TMZ and CAR-T, and that CAR-T-resistant cells grow and respond to TMZ exactly like sensitive cells; if double-resistant cells emerge, the alternating strategy loses its complementary control.

Editorial extensions

If this is right

  • An alternating schedule, starting with CAR-T and alternating with TMZ cycles, should be prioritized in future trial designs over giving all TMZ first or all CAR-T first.
  • Constant daily administration of both therapies, with TMZ efficacy and CAR-T dose above the thresholds in Proposition 6, would suffice for tumor eradication in the model.
  • Tumor proliferation rate, TMZ killing efficacy, and tumor-induced immunosuppression are the survival biomarkers that most influence outcomes, with immunosuppression being the main factor limiting CAR-T monotherapy.
  • For tumors whose TMZ-resistant cells grow as fast as or faster than sensitive cells, adding TMZ to CAR-T can reduce survival relative to CAR-T alone, so protocols should be stratified by resistance phenotype.

Reading between the lines

Editorial extensions of the paper, not claims the author makes directly.

  • A direct extension not pursued in the paper: the same alternating logic should be tested in other solid tumors with heterogeneous antigen expression, where chemotherapy can reduce the antigen-negative population and CAR-T can clear the chemo-resistant one.
  • One could test the model's mechanism by adding a fourth tumor compartment resistant to both treatments; if double-resistant cells arise at clinically relevant rates, the predicted superiority of alternating schedules would likely shrink or disappear.
  • The protocol-equivalence analysis, in which roughly 61–75% of virtual patients achieve similar survival under any protocol, suggests that only a minority of patients need personalized sequencing; identifying those patients by low immunosuppression and high growth rate could be a prospective stratification.
  • A testable corollary is that the timing gap between CAR-T injections matters less than dose or sequence, since the model shows only a slight survival decline as the gap increases.
Share X Bluesky LinkedIn Reddit HN

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, and a circularity audit.

Referee Report

4 major / 6 minor

Summary. The manuscript introduces a five-dimensional ODE model of malignant glioma growth under combined temozolomide (TMZ) and CAR-T cell therapy. The state variables are TMZ-sensitive/CAR-T-sensitive cells (S), CAR-T-resistant but TMZ-sensitive cells (RC), TMZ-resistant but CAR-T-sensitive cells (RE), CAR-T cells (C), and normalized TMZ efficacy (E). The authors prove non-negativity of solutions, identify invariant surfaces, analyze isolated equilibria, and give explicit conditions for local stability of a tumor-free equilibrium under constant daily administration of both therapies. They then simulate a cohort of 10^4 virtual patients with parameters sampled uniformly from literature-based ranges and compare several finite impulsive protocols: TMZ monotherapy, CAR-T monotherapy, and six combined schedules. The central numerical claim is that alternating schedules, specifically 5T2C5T and 1C5T1C5T, give the best median survival, approximately 650 days for r2=r1/2, and that the main survival determinants are tumor growth rate r1, TMZ efficacy alpha1, and tumor-induced CAR-T inactivation rho4.

Significance. If the conclusions are robust, the paper provides a useful in silico framework for comparing TMZ/CAR-T scheduling in malignant glioma, with the notable strength of an explicit analytic condition for the tumor-free equilibrium under constant treatment (Proposition 6) and a fully reproducible virtual-patient protocol whose code is stated to be available on GitHub. The correlation analyses between survival and model parameters are clearly presented and could inform design of future experimental or clinical studies. However, the central protocol recommendation depends on several assumptions whose robustness is not established: the exclusion of double-resistant tumor cells, a post hoc restriction of the rho4 range, and unverified parameter identifications such as alpha3=alpha1. These assumptions are load-bearing because the alternating-protocol synergy relies on the two resistance mechanisms being complementary and on CAR-T cells surviving TMZ exposure; if either assumption fails, the predicted ranking of protocols could change substantially.

major comments (4)
  1. [Section II A, Eqs. (1)-(3); Section III B 3; Table VI] The manuscript explicitly excludes tumor cells resistant to both TMZ and CAR-T therapy (Section II A: 'we do not include populations resistant to both TMZ and CAR-T therapy'). This exclusion is load-bearing for the main protocol recommendation. The alternating-protocol benefit arises precisely because TMZ controls the CAR-T-resistant clone RC and CAR-T controls the TMZ-resistant clone RE; if a double-resistant clone D exists, neither treatment removes it, all tested protocols converge to the outgrowth time of D, and the 5T2C5T/1C5T1C5T advantage over other schedules may disappear. The virtual cohort samples initial fractions delta1 and delta2 but has no delta3 for double resistance, so the 10^4-patient trials cannot reveal this failure mode, and Proposition 6's tumor-free equilibrium no longer exists once D is present. Please add a sensitivity analysis that includes a double-resistant compartment (or an explicit, evidence-based argument for why such a population cannot arise in malignant glioma) and state how the protocol ranking changes with the initial fraction and growth rate of D.
  2. [Section II D and Fig. 6] The upper bound of rho4 is set to 0.1 in all subsequent simulations 'because the median survival time drops sharply if we increase this boundary further (see Fig. 6)'. This is a post hoc model-selection step based on the survival endpoint itself, and it has direct consequences for the reported efficacy of CAR-T-containing protocols: if the biologically plausible upper bound of rho4 were larger, the absolute and relative benefits of CAR-T and combined protocols would shrink substantially (as Fig. 6 shows for CAR-T monotherapy). The authors should either justify the 0.1 cap with independent data on tumor-induced immunosuppression in gliomas or report the sensitivity of the protocol ranking and median survival times to the chosen rho4 range.
  3. [Section III A (Proposition 6) and Section IV B] Proposition 6 establishes local stability of the tumor-free equilibrium for constant daily administration of both therapies (constant inputs ar v and ar E0). However, Section IV B states that administering doses 'above the critical thresholds' a finite number of times drives the system 'towards a tumor-free equilibrium'. This is not supported by the analysis: after the last impulsive dose, E decays to zero and C decays or is inactivated, and the tumor regrows, consistent with Proposition 5 and with the simulation results, which measure survival time to the fatal threshold K/5 rather than eradication. The finite-protocol simulations should be described as delaying tumor progression, not as steering the system to the tumor-free equilibrium; otherwise the quantitative claim in the discussion overstates what Proposition 6 and the in silico trials demonstrate.
  4. [Section II B 2 (Table I) and Section III B 3] The assumption alpha3 = alpha1 for TMZ killing of CAR-T cells is stated without direct experimental support and is not subjected to sensitivity analysis. Since alpha3 controls the survival of CAR-T cells during TMZ cycles, it directly affects the relative performance of alternating protocols versus TMZ-first or TMZ-last protocols: if TMZ kills CAR-T cells more effectively than tumor cells, the benefit of alternating schedules could be reduced or reversed, whereas if alpha3 is much smaller than alpha1, the benefit could be amplified. The main protocol recommendation therefore depends on an unquantified parameter. Please add a sensitivity analysis over alpha3/alpha1 in a plausible range, or provide direct evidence justifying the identification.
minor comments (6)
  1. [Section III A, proof of Proposition 3] In the proof of Proposition 3, the text writes f4(S,RC,RE,0,E)=v, but the system (1)-(5) has no v term in Eq. (4); for the original system this value is 0. The formula presumably refers to the impulsive or constant-treatment variant, and should be corrected for clarity.
  2. [Table I and Section II B 3] The initial total tumor size T0 appears in many correlation tables (Tables II-V, VII-X, XII, XIV-XVII) but is not listed in Table I and no sampling distribution or reference value is specified for it. Please add T0 with its range and rationale so that the virtual-patient protocol is reproducible.
  3. [Proposition 5, Eq. (13)] The expression for lambda2 repeats the term rho2 S1/(g1+S1) twice; it should evidently contain the corresponding RE term rho3 RE/(g2+RE). The inequality that follows suggests this is a typographical error, but it makes the displayed formula incorrect as written.
  4. [Section IV D] In the discussion of CAR-T monotherapy correlations, the text refers to 'the fraction of tumor cells resistant to CAR-T therapy, delta1'; the correct parameter is delta2, the initial fraction of RC cells. Also, Table XVII lists delta1 twice with different correlation values; the second row should presumably be delta2.
  5. [Section III B 3, Table VI] The difference between the two leading protocols, 5T2C5T and 1C5T1C5T, is 1-2 days in median survival (652 vs. 653 days for 2v=10^9; 689 vs. 688 days for 2v=2e9). This difference is far smaller than the spread within each protocol, so statements that these two are 'the best' should be accompanied by a statistical comparison (e.g., confidence intervals for the median or a paired test) to show that their ranking relative to each other and to 2C10T is meaningful.
  6. [Throughout] Pearson correlation p-values are reported as 0.00 in several tables; please report them as p<0.001 or with the actual numerical values, and note that a p-value of exactly zero for a finite Monte Carlo sample is not statistically meaningful.

Circularity Check

0 steps flagged · score 2.0 of 10

No significant circularity: the in silico protocol ranking is computed from an explicitly stated model, not fitted to the target conclusion; self-citations and the disclosed no-double-resistant assumption are not load-bearing circular reductions.

full rationale

The paper's central claims (median survival under 5T2C5T and 1C5T1C5T, Proposition 6's tumor-free equilibrium conditions, and parameter correlations) are outputs of the explicitly stated ODE system (1)-(5) with parameters listed in Table I and a transparently described virtual-patient cohort. No parameter is fitted to the survival endpoints being predicted; the protocol comparison is a forward simulation of the same cohort under different treatment schedules. The alternating-therapy recommendation follows from the model's explicit compartmental structure: RE is TMZ-resistant but CAR-T-sensitive, RC is CAR-T-resistant but TMZ-sensitive, and no double-resistant population is included. This is a stated modeling assumption in Section II A, not a circular redefinition. Proposition 6 is an analytic eigenvalue calculation, not an imported uniqueness theorem. Self-citations to the authors' prior CAR-T modeling work [20,65] supply equation forms and the carrying capacity K, but the equations are reproduced in the text and the protocol ranking is computed within the present model, so those citations are not load-bearing. Two caveats are disclosed and weighed here but do not amount to circularity: the upper bound on rho4 is capped at 0.1 after a sensitivity analysis showing sharply declining survival, and the exclusion of double-resistant tumor cells is clinically load-bearing for the recommendation. Both are modeling and sensitivity choices stated in the manuscript, so the derivation remains self-contained rather than circular.

Assumptions & free parameters 5 free parameters · 5 assumptions · 0 invented entities

The model's central predictions rest on several assumed parameter values and structural modeling choices that are not fitted to patient data. The most consequential choices are the equal growth/TMZ-sensitivity assumption for CAR-T-resistant cells, the absence of double-resistant cells, and the outcome-dependent cap on rho4. No genuinely new physical or biological entities are introduced.

free parameters (5)
  • r2 (TMZ-resistant growth rate) = r1/2 in baseline, varied to r1 and 2r1
    Assumed because the relative growth of TMZ-resistant cells is not well characterized; the paper later relaxes this assumption.
  • alpha3 (TMZ killing efficacy against CAR-T cells) = alpha1
    Assumed equal to TMZ efficacy against tumor cells because no direct measurements exist for CAR-T cells in MG patients.
  • delta1 (initial fraction of TMZ-resistant cells) = uniform in [1e-4, 0.1]
    Assumed range because intrinsic TMZ resistance is not clearly characterized in the literature.
  • rho4 upper bound = 0.1
    The upper bound is set after observing that median survival drops sharply when rho4 increases beyond this value, a post hoc choice that affects CAR-T monotherapy results.
  • L2 (number of CAR-T injections) = 2
    Assumed to balance clinical toxicity concerns; the paper notes L2=1 gives slightly better survival but is less practical.
assumptions (5)
  • domain assumption All tumor compartments grow logistically with a common carrying capacity K.
    Introduced in Eq. (1)-(3) and Section II A; no evidence that the three subpopulations share the same carrying capacity.
  • domain assumption TMZ resistance is acquired at rate epsilon1 proportional to TMZ efficacy and sensitive cell abundance, with no intermediate resistant state.
    Used in Eq. (3) and justified by a simplified approach compared to Ref. [56].
  • domain assumption CAR-T cell proliferation and inactivation follow Michaelis-Menten saturation terms with fixed half-saturation constants.
    Equation (4) and Table I; these functional forms are standard in prior CAR-T models but not derived here.
  • domain assumption TMZ follows first-order exponential decay with rate mu.
    Equation (5) and Ref. [68]; a simplified pharmacokinetic model.
  • standard math Essential nonnegativity criterion from Haddad and Chellaboina (Proposition 1).
    Used to prove nonnegativity of solutions in Proposition 3.

how reviews work

0 comments
Cite this review

Pith. "Pith review of A mathematical model of CAR-T cell therapy in combination with chemotherapy for malignant gliomas." pith.science (2026). https://pith.science/paper/VAHSDG7Y

@misc{pith2026250113774,
  author       = {Pith},
  title        = {Pith review of: A mathematical model of CAR-T cell therapy in combination with chemotherapy for malignant gliomas},
  year         = {2026},
  howpublished = {\url{https://pith.science/paper/VAHSDG7Y}},
  note         = {Machine review of arXiv:2501.13774}
}
abstract

We study the dynamics and interactions between combined chemotherapy and chimeric antigen receptor (CAR-T) cells therapy and malignant gliomas (MG). MG is one of the most common primary brain tumor, with high resistance to therapy and unfavorable prognosis. Here, we develop a mathematical model that describes the application of chemo- and CAR-T cell therapies and the dynamics of sensitive and resistant populations of tumor cells. This model is a five-dimensional dynamical system with impulsive inputs corresponding to clinical administration of chemo- and immunotherapy. We provide a proof of non-negativeness of solutions of the proposed model for non-negative initial data. We demonstrate that if we apply both therapies only once, the trajectories will be attracted to an invariant surface that corresponds to the tumor carrying capacity. On the other hand, if we apply both treatments constantly, we find regions of the parameter where the tumor is eradicated. Moreover, we study applications of different combinations of the above treatments in order to find an optimal combination at the population level. To this aim, we generate a population of $10^{4}$ virtual patients with the model parameters uniformly distributed in the medically relevant ranges and perform \emph{in silico} trials with different combinations of treatments. We obtain optimal protocols for several different relations of tumor growth rates between sensitive and drug resistant cells. We demonstrate that the tumor growth rate, efficacy of chemotherapy, and tumor immunosuppression are the parameters that mostly impact survival time in \emph{in silico} trials. We believe that our results provide new theoretical insights to guide the design of clinical trials for MG therapies.

Figures

Figures reproduced from arXiv: 2501.13774 by the authors.

Figure 1
Figure 1. FIG. 1. Graphical representation of the model variables and [PITH_FULL_IMAGE:figures/full_fig_p003_1.png] view at source ↗
Figure 3
Figure 3. FIG. 3. Kaplan–Meier curves and risk table comparing 10 [PITH_FULL_IMAGE:figures/full_fig_p011_3.png] view at source ↗
Figure 2
Figure 2. FIG. 2. The dependence of the median survival time for treat [PITH_FULL_IMAGE:figures/full_fig_p011_2.png] view at source ↗
Figures from the paper (23 more)
Figure 4
Figure 4. Figure 4: FIG. 4. The dynamics of different tumor compartments and [PITH_FULL_IMAGE:figures/full_fig_p012_4.png]
Figure 6
Figure 6. Figure 6: FIG. 6. The dependence of the the median survival time [PITH_FULL_IMAGE:figures/full_fig_p012_6.png]
Figure 5
Figure 5. Figure 5: FIG. 5. Correlation between the improvement of survival tim [PITH_FULL_IMAGE:figures/full_fig_p012_5.png]
Figure 8
Figure 8. Figure 8: FIG. 8. The dependence of the median survival time [PITH_FULL_IMAGE:figures/full_fig_p013_8.png]
Figure 7
Figure 7. Figure 7: FIG. 7. The dependence of [PITH_FULL_IMAGE:figures/full_fig_p013_7.png]
Figure 11
Figure 11. Figure 11: FIG. 11. Correlation between [PITH_FULL_IMAGE:figures/full_fig_p014_11.png]
Figure 10
Figure 10. Figure 10: FIG. 10. The dynamics of different tumor compartments and [PITH_FULL_IMAGE:figures/full_fig_p014_10.png]
Figure 12
Figure 12. Figure 12: FIG. 12. KM curves and risk tables comparing the 5T2C5T [PITH_FULL_IMAGE:figures/full_fig_p015_12.png]
Figure 13
Figure 13. Figure 13: FIG. 13. Dynamics for the MVP under the 5T2C5T protocol [PITH_FULL_IMAGE:figures/full_fig_p015_13.png]
Figure 14
Figure 14. Figure 14: FIG. 14. KM curves and risk tables comparing the 1C5T1C5T [PITH_FULL_IMAGE:figures/full_fig_p016_14.png]
Figure 15
Figure 15. Figure 15: FIG. 15. Dynamics for the MVP under the 1C5T1C5T pro [PITH_FULL_IMAGE:figures/full_fig_p016_15.png]
Figure 16
Figure 16. Figure 16: FIG. 16. Box plot showing the efficacy of combined protocols [PITH_FULL_IMAGE:figures/full_fig_p017_16.png]
Figure 18
Figure 18. Figure 18: FIG. 18. The correlation between the fraction [PITH_FULL_IMAGE:figures/full_fig_p018_18.png]
Figure 17
Figure 17. Figure 17: FIG. 17. A comparison of tumor dynamics for 2 different [PITH_FULL_IMAGE:figures/full_fig_p018_17.png]
Figure 20
Figure 20. Figure 20: FIG. 20. Box plot showing the efficacy of the selected com [PITH_FULL_IMAGE:figures/full_fig_p019_20.png]
Figure 23
Figure 23. Figure 23: FIG. 23. Dynamics for the MVP (left) and KM curve (right) [PITH_FULL_IMAGE:figures/full_fig_p020_23.png]
Figure 21
Figure 21. Figure 21: FIG. 21. Dynamics for the MVP (left) and KM curves (right) [PITH_FULL_IMAGE:figures/full_fig_p020_21.png]
Figure 22
Figure 22. Figure 22: FIG. 22. Dynamics for the MVP (left) and KM curve (right) [PITH_FULL_IMAGE:figures/full_fig_p020_22.png]
Figure 24
Figure 24. Figure 24: FIG. 24. Dynamics for the MVP (left) and KM curve (right) [PITH_FULL_IMAGE:figures/full_fig_p021_24.png]
Figure 25
Figure 25. Figure 25: FIG. 25. KM curves comparing the 10T and 5T1C5T1C pro [PITH_FULL_IMAGE:figures/full_fig_p025_25.png]
Figure 26
Figure 26. Figure 26: FIG. 26. Dynamics for the MVP under the 5T1C5T1C pro [PITH_FULL_IMAGE:figures/full_fig_p025_26.png]
Figure 29
Figure 29. Figure 29: FIG. 29. KM curves comparing the 10T and 1C10T1C pro [PITH_FULL_IMAGE:figures/full_fig_p026_29.png]
Figure 32
Figure 32. Figure 32: FIG. 32. Dynamics for the MVP under the 10T2C protocol [PITH_FULL_IMAGE:figures/full_fig_p026_32.png]

Discussion (0). Continue with ORCID to comment.

Reference graph

Works this paper leans on

75 extracted references · 67 canonical work pages

  1. [1]

    merlin.mbs aapmrev4-1.bst 2010-07-25 4.21a (PWD, AO, DPC) hacked

    FUNCTION id.bst "merlin.mbs aapmrev4-1.bst 2010-07-25 4.21a (PWD, AO, DPC) hacked" ENTRY address archive archivePrefix author bookaddress booktitle chapter collaboration doi edition editor eid eprint howpublished institution isbn issn journal key language month note number organization pages primaryClass publisher school SLACcitation series title translat...

    2010

  2. [2]

    merlin.mbs aipauth4-1.bst 2010-07-25 4.21a (PWD, AO, DPC) hacked

    FUNCTION id.bst "merlin.mbs aipauth4-1.bst 2010-07-25 4.21a (PWD, AO, DPC) hacked" ENTRY address archive archivePrefix author bookaddress booktitle chapter collaboration doi edition editor eid eprint howpublished institution isbn issn journal key language month note number organization pages primaryClass publisher school SLACcitation series title translat...

    2010

  3. [3]

    merlin.mbs aipnum4-1.bst 2010-07-25 4.21a (PWD, AO, DPC) hacked

    FUNCTION id.bst "merlin.mbs aipnum4-1.bst 2010-07-25 4.21a (PWD, AO, DPC) hacked" ENTRY address archive archivePrefix author bookaddress booktitle chapter collaboration doi edition editor eid eprint howpublished institution isbn issn journal key language month note number organization pages primaryClass publisher school SLACcitation series title translati...

    2010

  4. [4]

    merlin.mbs apsrev4-1.bst 2010-07-25 4.21a (PWD, AO, DPC) hacked

    FUNCTION id.bst "merlin.mbs apsrev4-1.bst 2010-07-25 4.21a (PWD, AO, DPC) hacked" ENTRY address archive archivePrefix author bookaddress booktitle chapter collaboration doi edition editor eid eprint howpublished institution isbn issn journal key language month note number organization pages primaryClass publisher school SLACcitation series title translati...

    2010

  5. [5]

    merlin.mbs apsrmp4-1.bst 2010-07-25 4.21a (PWD, AO, DPC) hacked

    FUNCTION id.bst "merlin.mbs apsrmp4-1.bst 2010-07-25 4.21a (PWD, AO, DPC) hacked" ENTRY address archive archivePrefix author bookaddress booktitle chapter collaboration doi edition editor eid eprint howpublished institution isbn issn journal key language month note number organization pages primaryClass publisher school SLACcitation series title translati...

    2010

  6. [6]

    Lerner , author K

    author author A. Lerner , author K. Palmer , author T. Campion , author T. Millner , author E. Scott , author C. Lorimer , author D. Paraskevopoulos , author G. McKenna , author S. Marino , author R. Lewis , \ and\ author N. Plowman ,\ title title Gliomas in adults: Guidance on investigations, diagnosis, treatment & surveillance , \ 10.1016/j.clinme.2024....

    arXiv

  7. [7]

    Stupp , author W

    author author R. Stupp , author W. P. \ Mason , author M. J. \ Van Den Bent , author M. Weller , author B. Fisher , author M. J. \ Taphoorn , author K. Belanger , author A. A. \ Brandes , author C. Marosi , author U. Bogdahn , et al. ,\ title title Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma , \ @noop journal journal New Engla...

    work page 2005

  8. [8]

    Filley , author M

    author author A. Filley , author M. Henriquez , \ and\ author M. Dey ,\ title title Cart immunotherapy: Development, success, and translation to malignant gliomas and other solid tumors , \ 10.3389/fonc.2018.00453 journal journal Frontiers in Oncology \ volume 8 ( year 2018 ),\ 10.3389/fonc.2018.00453 NoStop

    work page arXiv 2018

Show all 75 references
  1. [9]

    author author B. C. \ Thomas , author D. E. \ Staudt , author A. M. \ Douglas , author M. Monje , author N. A. \ Vitanza , \ and\ author M. D. \ Dun ,\ title title Car t cell therapies for diffuse midline glioma , \ 10.1016/j.trecan.2023.07.007 journal journal Trends in Cancer...

    doi

  2. [10]

    Montoya , author M

    author author M. Montoya , author M. Gallus , author S. Phyu , author J. Haegelin , author J. de Groot , \ and\ author H. Okada ,\ title title A roadmap of car-t-cell therapy in glioblastoma: Challenges and future perspectives , \ @noop journal journal Cells \ volume 13 ,\ pag...

    2024

  3. [11]

    Goutnik , author A

    author author M. Goutnik , author A. Lakovidis , author M. Still , author R. Moor , author K. Melnick , author S. Yan , author M. Abbas , \ and\ author A. Ghiaseddin ,\ title title Advancements in car-t cell therapy for glioblastoma multiforme: Literature review and future dir...

    doi

  4. [12]

    Feins , author W

    author author S. Feins , author W. Kong , author E. F. \ Williams , author M. C. \ Milone , \ and\ author J. A. \ Fraietta ,\ title title An introduction to chimeric antigen receptor (car) t-cell immunotherapy for human cancer , \ https://doi.org/10.1002/ajh.25418 journal jour...

    doi

  5. [13]

    author author S. L. \ Maude , author T. W. \ Laetsch , author J. Buechner , author S. Rives , author M. Boyer , author H. Bittencourt , author P. Bader , author M. R. \ Verneris , author H. E. \ Stefanski , author G. D. \ Myers , author M. Qayed , author B. De Moerloose , auth...

  6. [14]

    author author N. A. \ Miliotou \ and\ author C. L. \ Papadopoulou ,\ title title Car t-cell therapy: A new era in cancer immunotherapy , \ 10.2174/1389201019666180418095526 journal journal Current Pharmaceutical Biotechnology \ volume 19 ,\ pages 5--18 ( year 2018 ) NoStop

    doi

  7. [15]

    D'Agostino \ and\ author N

    author author M. D'Agostino \ and\ author N. Raje ,\ title title Anti-bcma car t-cell therapy in multiple myeloma: can we do better? \ 10.1038/s41375-019-0669-4 journal journal Leukemia \ volume 34 ,\ pages 21--34 ( year 2020 ) NoStop

    doi

  8. [16]

    author author J. C. \ Chavez , author C. Bachmeier , \ and\ author M. A. \ Kharfan-Dabaja ,\ title title Car t-cell therapy for b-cell lymphomas: clinical trial results of available products , \ 10.1177/2040620719841581 journal journal Therapeutic Advances in Hematology \ volu...

    doi

  9. [17]

    \ Wang , author Y

    author author Q.-S. \ Wang , author Y. Wang , author H.-Y. \ Lv , author Q.-W. \ Han , author H. Fan , author B. Guo , author L.-L. \ Wang , \ and\ author W.-D. \ Han ,\ title title Treatment of cd33-directed chimeric antigen receptor-modified t cells in one patient with relap...

    doi

  10. [18]

    Martinez \ and\ author E

    author author M. Martinez \ and\ author E. K. \ Moon ,\ title title Car t cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment , \ 10.3389/fimmu.2019.00128 journal journal Frontiers in Immunology \ volume 10 ( year 2019 ...

    2019

  11. [19]

    Bagley \ and\ author D

    author author S. Bagley \ and\ author D. O’Rourke ,\ title title Clinical investigation of car t cells for solid tumors: Lessons learned and future directions , \ 10.1016/j.pharmthera.2019.107419 journal journal Pharmacology & Therapeutics \ volume 205 ,\ pages 107419 ( year 2...

    2019

  12. [20]

    Castellarin , author K

    author author M. Castellarin , author K. Watanabe , author C. June , author C. Kloss , \ and\ author A. Posey ,\ title title Driving cars to the clinic for solid tumors , \ 10.1038/s41434-018-0007-x journal journal Gene Therapy \ volume 25 ( year 2018 ),\ 10.1038/s41434-018-00...

    doi

  13. [21]

    Kringel , author K

    author author R. Kringel , author K. Lamszus , \ and\ author M. Mohme ,\ title title Chimeric antigen receptor t cells in glioblastoma—current concepts and promising future , \ @noop journal journal Cells \ volume 12 ,\ pages 1770 ( year 2023 ) NoStop

    2023

  14. [22]

    author author K. M. \ Hege , author E. K. \ Bergsland , author G. A. \ Fisher , author J. J. \ Nemunaitis , author R. S. \ Warren , author J. G. \ McArthur , author A. A. \ Lin , author J. Schlom , author C. H. \ June , \ and\ author S. A. \ Sherwin ,\ title title Safety, tumo...

    doi

  15. [23]

    Ma , author X

    author author S. Ma , author X. Li , author X. Wang , author L. Cheng , author Z. Li , author C. Zhang , author Z. Ye , \ and\ author Q. Qian ,\ title title Current progress in car-t cell therapy for solid tumors , \ 10.7150/ijbs.34213 journal journal Int J Biol Sci \ volume 1...

    doi

  16. [24]

    Hong , author J

    author author M. Hong , author J. Clubb , \ and\ author Y. Chen ,\ title title Engineering car-t cells for next-generation cancer therapy , \ 10.1016/j.ccell.2020.07.005 journal journal Cancer Cell \ volume 38 ( year 2020 ),\ 10.1016/j.ccell.2020.07.005 NoStop

    2020 doi

  17. [25]

    Bodnar , author U

    author author M. Bodnar , author U. Foryś , author M. J. \ Piotrowska , author M. Bodzioch , author J. A. \ Romero-Rosales , \ and\ author J. Belmonte-Beitia ,\ title title On the analysis of a mathematical model of car–t cell therapy for glioblastoma: Insights from a mathemat...

    doi

  18. [26]

    Schmidts , author A

    author author A. Schmidts , author A. A. \ Srivastava , author R. Ramapriyan , author S. R. \ Bailey , author A. A. \ Bouffard , author D. P. \ Cahill , author B. S. \ Carter , author W. T. \ Curry , author G. P. \ Dunn , author M. J. \ Frigault , et al. ,\ title title Tandem ...

    2023

  19. [27]

    Bielamowicz , author K

    author author K. Bielamowicz , author K. Fousek , author T. Byrd , author H. Samaha , author M. Mukherjee , author N. Aware , author M.-F. \ Wu , author J. Orange , author P. Sumazin , author T.-K. \ Man , author S. Joseph , author M. Hegde , \ and\ author N. Ahmed ,\ title ti...

    doi

  20. [28]

    Weiss , author H

    author author T. Weiss , author H. Schneider , author M. Silginer , author A. Steinle , author M. Pruschy , author B. Poli \'c , author M. Weller , \ and\ author P. Roth ,\ title title Nkg2d-dependent antitumor effects of chemotherapy and radiotherapy against glioblastoma , \ ...

    2018

  21. [29]

    Monje , author J

    author author M. Monje , author J. Mahdi , author R. Majzner , author K. Yeom , author L. Schultz , author R. Richards , author V. Barsan , author K.-W. \ Song , author J. Kamens , author C. Baggott , author M. Kunicki , author S. Rietberg , author A. Lim , author A. Reschke ,...

  22. [30]

    author author C. M. \ Suryadevara , author R. Desai , author M. L. \ Abel , author K. A. \ Riccione , author K. A. \ Batich , author S. H. \ Shen , author P. Chongsathidkiet , author P. C. \ Gedeon , author A. A. \ Elsamadicy , author D. J. \ Snyder , et al. ,\ title title Tem...

    2018

  23. [31]

    Lamb , author L

    author author L. Lamb , author L. Pereboeva , author S. Youngblood , author G. Gillespie , author L. Nabors , author J. Markert , author A. Dasgupta , author C. Langford , \ and\ author H. Spencer ,\ title title A combined treatment regimen of mgmt-modified t cells and temozol...

    doi

  24. [32]

    Lamb , author M

    author author L. Lamb , author M. Lobbous , author T. Goswami , author K. Rochlin , author J. Shepard , author B. Weekley , author C. Lucas , author C. Langford , author S. Youngblood , author M. ter Haak , \ and\ author L. Nabors ,\ title title 637 inb-200: Phase i study of g...

  25. [33]

    author author J. L. \ Gevertz \ and\ author J. R. \ Wares ,\ title title Assessing the role of patient generation techniques in virtual clinical trial outcomes , \ @noop journal journal Bulletin of Mathematical Biology \ volume 86 ,\ pages 119 ( year 2024 ) NoStop

    2024

  26. [34]

    Wang , author T

    author author H. Wang , author T. Arulraj , author A. Ippolito , \ and\ author A. S. \ Popel ,\ title title From virtual patients to digital twins in immuno-oncology: lessons learned from mechanistic quantitative systems pharmacology modeling , \ @noop journal journal NPJ Digi...

    2024

  27. [35]

    author author L. V. \ Brown , author J. Wagg , author R. Darley , author A. van Hateren , author T. Elliott , author E. A. \ Gaffney , \ and\ author M. C. \ Coles ,\ title title De-risking clinical trial failure through mechanistic simulation , \ @noop journal journal Immunoth...

    2022

  28. [36]

    Altrock , author L

    author author P. Altrock , author L. Liu , \ and\ author F. Michor ,\ title title The mathematics of cancer: Integrating quantitative models , \ 10.1038/nrc4029 journal journal Nature Reviews Cancer \ volume 15 ,\ pages 730--745 ( year 2015 ) NoStop

    doi

  29. [37]

    Sahoo , author X

    author author P. Sahoo , author X. Yang , author D. Abler , author D. Maestrini , author V. Adhikarla , author D. Frankhouser , author H. Cho , author V. Machuca , author D. Wang , author M. Barish , author M. Gutova , author S. Branciamore , author C. E. \ Brown , \ and\ auth...

  30. [38]

    author author G. J. \ Kimmel , author F. L. \ Locke , \ and\ author P. M. \ Altrock ,\ title title The roles of T cell competition and stochastic extinction events in chimeric antigen receptor T cell therapy , \ 10.1098/rspb.2021.0229 journal journal Proceedings of the Royal S...

  31. [39]

    author author L. R. C. \ Barros , author B. d. J. \ Rodrigues , \ and\ author R. C. \ Almeida ,\ title title CAR-T cell Goes on a Mathematical Model , \ 10.33696/immunology.2.016 journal journal Journal of Cellular Immunology \ volume 2 ,\ pages 31--37 ( year 2020 ) NoStop

    doi

  32. [40]

    Mostolizadeh , author Z

    author author R. Mostolizadeh , author Z. Afsharnezhad , \ and\ author A. Marciniak-Czochra ,\ title title Mathematical model of chimeric anti-gene receptor (car) t cell therapy with presence of cytokine , \ @noop journal journal Numerical Algebra, Control and Optimization \ v...

    2018

  33. [41]

    Le\'on-Triana , author S

    author author O. Le\'on-Triana , author S. Soukaina , author G. Calvo , author J. Belmonte-Beitia , author S. Chuli\'an , author A. Mart\'inez-Rubio , author M. Rosa , author A. P\'erez-Mart\'inez , author M. Ramirez-Orellana , \ and\ author V. P\'erez-Garc\'ia ,\ title title ...

  34. [42]

    P\'erez-Garc\'ia , author G

    author author V. P\'erez-Garc\'ia , author G. Calvo , author J. Bosque , author O. Le\'on-Triana , author J. Jim\'enez Sánchez , author J. P\'erez Beteta , author J. Belmonte-Beitia , author M. Valiente , author L. Zhu , author P. Garc\'ia G\'omez , author P. S\'anchez-G\'omez...

  35. [43]

    Serrano , author R

    author author S. Serrano , author R. Barrio , author l. Martínez-Rubio , author J. Belmonte-Beitia , \ and\ author V. M. \ Pérez-García ,\ title title Understanding the role of B cells in CAR T-cell therapy in leukemia through a mathematical model , \ 10.1063/5.0206341 journal...

    doi

  36. [44]

    author author H. S. \ Friedman , author T. Kerby , \ and\ author H. Calvert ,\ title title Temozolomide and treatment of malignant glioma , \ @noop journal journal Clinical cancer research \ volume 6 ,\ pages 2585--2597 ( year 2000 ) NoStop

    2000

  37. [45]

    Le\' o n-Triana , author A

    author author O. Le\' o n-Triana , author A. Perez-Martinez , author M. Ramirez-Orellana , \ and\ author V. Perez-Garcia ,\ title title Dual-target car-ts with on- and off-tumour activity may override immune suppression in solid cancers: A mathematical proof of concept , \ 10....

    doi

  38. [46]

    author author D. S. \ Santurio \ and\ author L. R. C. \ Barros ,\ title title A mathematical model for on-target off-tumor effect of car-t cells on gliomas , \ @noop journal journal Frontiers in Systems Biology \ volume 2 ,\ pages 923085 ( year 2022 ) NoStop

    2022

  39. [47]

    Ghorashian , author A

    author author S. Ghorashian , author A. Kramer , author S. Onuoha , \ and\ author et al ,\ title title Enhanced car t cell expansion and prolonged persistence in pediatric patients with all treated with a low-affinity cd19 car , \ https://doi.org/10.1038/s41591-019-0549-5 jour...

    doi

  40. [48]

    Delobel , author L

    author author T. Delobel , author L. E. \ Ayala-Hernández , author J. Bosque , author J. Pérez Beteta , author S. Chulián , author M. García-Ferrer , author P. Piñero , author P. Schucht , author M. Murek , \ and\ author V. Pérez-García ,\ title title Overcoming chemotherapy r...

    doi

  41. [49]

    Bodnar , author M

    author author M. Bodnar , author M. Piotrowska , author M. Bodzioch , author J. Belmonte-Beitia , \ and\ author U. Foryś ,\ title title Dual car-t cell therapy for glioblastoma: strategies to cure tumour diseases based on a mathematical model , \ 10.1007/s11071-024-10258-x jou...

    doi

  42. [50]

    author author S. L. \ Goff , author R. A. \ Morgan , author J. C. \ Yang , author R. M. \ Sherry , author P. F. \ Robbins , author N. P. \ Restifo , author S. A. \ Feldman , author Y.-C. \ Lu , author L. Lu , author Z. Zheng , et al. ,\ title title Pilot trial of adoptive tran...

    2019

  43. [51]

    author author D. M. \ O’Rourke , author M. P. \ Nasrallah , author A. Desai , author J. J. \ Melenhorst , author K. Mansfield , author J. J. \ Morrissette , author M. Martinez-Lage , author S. Brem , author E. Maloney , author A. Shen , et al. ,\ title title A single dose of p...

    2017

  44. [52]

    Portnow , author B

    author author J. Portnow , author B. Badie , author M. Chen , author A. Liu , author S. Blanchard , \ and\ author T. W. \ Synold ,\ title title The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach t...

    2009

  45. [53]

    Italia , author K

    author author M. Italia , author K. Y. \ Wertheim , author S. Taschner-Mandl , author D. Walker , \ and\ author F. Dercole ,\ title title Mathematical model of clonal evolution proposes a personalised multi-modal therapy for high-risk neuroblastoma , \ @noop journal journal Ca...

    1986

  46. [54]

    Campos , author Z

    author author B. Campos , author Z. Gal , author A. Baader , author T. Schneider , author C. Sliwinski , author K. Gassel , author J. Bageritz , author N. Grabe , author A. Von Deimling , author P. Beckhove , et al. ,\ title title Aberrant self-renewal and quiescence contribut...

    2014

  47. [55]

    author author A. A. \ Stepanenko , author S. V. \ Andreieva , author K. V. \ Korets , author D. O. \ Mykytenko , author V. P. \ Baklaushev , author N. L. \ Huleyuk , author O. A. \ Kovalova , author K. V. \ Kotsarenko , author V. P. \ Chekhonin , author Y. S. \ Vassetzky , et ...

    2016

  48. [56]

    author author A. L. \ Yuan , author C. B. \ Ricks , author A. K. \ Bohm , author X. Lun , author L. Maxwell , author S. Safdar , author S. Bukhari , author A. Gerber , author W. Sayeed , author E. A. \ Bering , et al. ,\ title title Abt-888 restores sensitivity in temozolomide...

    2018

  49. [57]

    Dai , author Y

    author author S. Dai , author Y. Yan , author Z. Xu , author S. Zeng , author L. Qian , author L. Huo , author X. Li , author L. Sun , \ and\ author Z. Gong ,\ title title Scd1 confers temozolomide resistance to human glioma cells via the akt/gsk3 / -catenin signaling axis , \...

    2018

  50. [58]

    author author S. K. \ Gupta , author A. C. \ Mladek , author B. L. \ Carlson , author F. Boakye-Agyeman , author K. K. \ Bakken , author S. H. \ Kizilbash , author M. A. \ Schroeder , author J. Reid , \ and\ author J. N. \ Sarkaria ,\ title title Discordant in vitro and in viv...

    2014

  51. [59]

    author author M. S. \ Tomar , author A. Kumar , author C. Srivastava , \ and\ author A. Shrivastava ,\ title title Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. \ @noop journal journal Biochimica et Biophysica A...

    2021

  52. [60]

    Bernstein \ and\ author S

    author author D. Bernstein \ and\ author S. Bhat ,\ title title Nonnegativity, reducibility, and semistability of mass action kinetics , \ 10.1109/CDC.1999.831248 journal journal Proceedings of the IEEE Conference on Decision and Control \ volume 3 ,\ pages 2206 -- 2211 vol.3 ...

    1999

  53. [61]

    Haddad \ and\ author V

    author author W. Haddad \ and\ author V. Chellaboina ,\ title title Stability and dissipativity theory for nonnegative dynamical systems: A unified analysis framework for biological and physiological systems , \ 10.1016/j.nonrwa.2004.01.006 journal journal Nonlinear Analysis: ...

    doi

  54. [62]

    author author J. H. \ Creed , author T. A. \ Gerke , \ and\ author A. E. \ Berglund ,\ title title Matsurv: Survival analysis and visualization in matlab , \ @noop journal journal Journal of Open Source Software \ volume 5 ,\ pages 1830 ( year 2020 ) NoStop

    2020

  55. [63]

    author author S. Y. \ Lee ,\ title title Temozolomide resistance in glioblastoma multiforme , \ @noop journal journal Genes & diseases \ volume 3 ,\ pages 198--210 ( year 2016 ) NoStop

    2016

  56. [64]

    author author J. G. \ Scott , author J. H. \ Suh , author P. Elson , author G. H. \ Barnett , author M. A. \ Vogelbaum , author D. M. \ Peereboom , author G. H. \ Stevens , author H. Elinzano , \ and\ author S. T. \ Chao ,\ title title Aggressive treatment is appropriate for g...

    2011

  57. [65]

    Li , author R

    author author J. Li , author R. Liang , author C. Song , author Y. Xiang , \ and\ author Y. Liu ,\ title title Prognostic significance of epidermal growth factor receptor expression in glioma patients , \ @noop journal journal OncoTargets and therapy \ ,\ pages 731--742 ( year...

    2018

  58. [66]

    \ Chen , author D.-S

    author author W.-J. \ Chen , author D.-S. \ He , author R.-X. \ Tang , author F.-H. \ Ren , \ and\ author G. Chen ,\ title title Ki-67 is a valuable prognostic factor in gliomas: evidence from a systematic review and meta-analysis , \ @noop journal journal Asian Pacific Journa...

    2015

  59. [67]

    Skaga , author E

    author author E. Skaga , author E. Kulesskiy , author S. Potdar , author I. Panagopoulos , author F. Micci , author I. A. \ Langmoen , author C. J. \ Sandberg , \ and\ author E. O. \ Vik-Mo ,\ title title Functional temozolomide sensitivity testing of patient-specific glioblas...

    2022

  60. [68]

    Chen , author R

    author author M. Chen , author R. Sun , author B. Shi , author Y. Wang , author S. Di , author H. Luo , author Y. Sun , author Z. Li , author M. Zhou , \ and\ author H. Jiang ,\ title title Antitumor efficacy of chimeric antigen receptor t cells against egfrviii-expressing gli...

    2019

  61. [69]

    Agosti , author A

    author author E. Agosti , author A. Garaba , author S. Antonietti , author T. Ius , author M. M. \ Fontanella , author M. Zeppieri , \ and\ author P. P. \ Panciani ,\ title title Car-t cells therapy in glioblastoma: a systematic review on molecular targets and treatment strate...

    2024

  62. [70]

    Sterner \ and\ author R

    author author R. Sterner \ and\ author R. Sterner ,\ title title Car-t cell therapy: current limitations and potential strategies , \ 10.1038/s41408-021-00459-7 journal journal Blood Cancer Journal \ volume 11 ,\ pages 69 ( year 2021 ) NoStop

    doi

  63. [71]

    Xu , author L

    author author S. Xu , author L. Tang , author X. Li , author F. Fan , \ and\ author Z. Liu ,\ title title Immunotherapy for glioma: current management and future application , \ @noop journal journal Cancer letters \ volume 476 ,\ pages 1--12 ( year 2020 ) NoStop

    2020

  64. [72]

    author author R. A. \ Gatenby , author J. Brown , \ and\ author T. Vincent ,\ title title Lessons from applied ecology: cancer control using an evolutionary double bind , \ @noop journal journal Cancer research \ volume 69 ,\ pages 7499--7502 ( year 2009 ) NoStop

    2009

  65. [73]

    author author P. A. \ Orlando , author R. A. \ Gatenby , \ and\ author J. S. \ Brown ,\ title title Cancer treatment as a game: integrating evolutionary game theory into the optimal control of chemotherapy , \ @noop journal journal Physical biology \ volume 9 ,\ pages 065007 (...

    2012

  66. [74]

    Italia , author F

    author author M. Italia , author F. Dercole , \ and\ author R. Lucchetti ,\ title title Optimal chemotherapy counteracts cancer adaptive resistance in a cell-based, spatially-extended, evolutionary model , \ @noop journal journal Physical Biology \ volume 19 ,\ pages 026004 ( ...

    2022

  67. [75]

    Owens , author A

    author author K. Owens , author A. Rahman , \ and\ author I. Bozic ,\ title title Spatiotemporal dynamics of tumor-car t-cell interaction following local administration in solid cancers , \ @noop journal journal bioRxiv \ ( year 2024 ) NoStop

    2024

Pith tools

Reviewed August 10, 2026 · model on record in the stance chip above.